- Home
- COYA vs PMVP Comparison
COYA vs PMVP Comparison
Compare COYA & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COYA
- PMVP
- Stock Information
- Founded
- COYA 2020
- PMVP 2013
- Country
- COYA United States
- PMVP United States
- Employees
- COYA N/A
- PMVP N/A
- Industry
- COYA Biotechnology: Pharmaceutical Preparations
- PMVP Medicinal Chemicals and Botanical Products
- Sector
- COYA Health Care
- PMVP Health Care
- Exchange
- COYA Nasdaq
- PMVP Nasdaq
- Market Cap
- COYA 104.3M
- PMVP 85.5M
- IPO Year
- COYA 2022
- PMVP 2020
- Fundamental
- Price
- COYA $5.74
- PMVP $1.51
- Analyst Decision
- COYA Strong Buy
- PMVP Strong Buy
- Analyst Count
- COYA 4
- PMVP 4
- Target Price
- COYA $16.25
- PMVP $5.75
- AVG Volume (30 Days)
- COYA 70.0K
- PMVP 196.4K
- Earning Date
- COYA 11-06-2024
- PMVP 11-07-2024
- Dividend Yield
- COYA N/A
- PMVP N/A
- EPS Growth
- COYA N/A
- PMVP N/A
- EPS
- COYA N/A
- PMVP N/A
- Revenue
- COYA $9,554,315.00
- PMVP N/A
- Revenue This Year
- COYA N/A
- PMVP N/A
- Revenue Next Year
- COYA $87.80
- PMVP N/A
- P/E Ratio
- COYA N/A
- PMVP N/A
- Revenue Growth
- COYA N/A
- PMVP N/A
- 52 Week Low
- COYA $4.75
- PMVP $1.40
- 52 Week High
- COYA $10.69
- PMVP $3.47
- Technical
- Relative Strength Index (RSI)
- COYA 36.62
- PMVP 38.59
- Support Level
- COYA $5.40
- PMVP $1.55
- Resistance Level
- COYA $6.44
- PMVP $1.61
- Average True Range (ATR)
- COYA 0.35
- PMVP 0.07
- MACD
- COYA -0.02
- PMVP -0.01
- Stochastic Oscillator
- COYA 17.78
- PMVP 18.18
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.